辉瑞已落在百时美施贵宝（BMS）和美国默克（Merck）等竞争对手后面，后两者已推出第一波免疫疗法药物——检查点抑制剂（checkpointinhibitor）。
Pfizer has fallen behind rivals such as Bristol-Myers Squibb and US Merck , which have already launched the first wave of immunotherapies , known as checkpoint inhibitors .
免疫检查点